Generate Investment Management Ltd acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the 1st quarter, HoldingsChannel reports. The fund acquired 4,908 shares of the biopharmaceutical company’s stock, valued at approximately $3,792,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Nordea Investment Management AB grew its position in shares of Regeneron Pharmaceuticals by 118.1% during the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after acquiring an additional 74,350 shares during the period. TD Asset Management Inc raised its holdings in Regeneron Pharmaceuticals by 15.9% in the 3rd quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock worth $210,437,000 after purchasing an additional 51,407 shares during the period. Mackenzie Financial Corp boosted its position in Regeneron Pharmaceuticals by 26.8% during the third quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock worth $72,321,000 after purchasing an additional 27,205 shares in the last quarter. Lockheed Martin Investment Management Co. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $2,702,000. Finally, Asio Capital LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $3,422,000. Institutional investors and hedge funds own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Price Performance
NASDAQ:REGN opened at $612.50 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $507.61 and a one year high of $821.11. The stock has a market cap of $64.75 billion, a PE ratio of 14.92, a P/E/G ratio of 1.34 and a beta of 0.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The stock has a 50 day moving average price of $673.70 and a 200 day moving average price of $731.25.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.
Insider Activity
In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have recently commented on REGN. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. TD Cowen increased their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $792.65.
View Our Latest Research Report on REGN
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
